{"organizations": [], "uuid": "61192a45c278252fee1c621214c817b64007a7d7", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.bio-medicine.org", "main_image": "", "site_section": "http://www.bio-medicine.org/inc/biomed/medicine-technology.asp", "section_title": "Latest Medical Technology from Bio-Medicine.Org", "url": "http://www.bio-medicine.org/medicine-technology-1/Valeant-Pharmaceuticals-Reports-Third-Quarter-2015-Financial-Results-49035-1/", "country": "US", "title": "Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results", "performance_score": 0, "site": "bio-medicine.org", "participants_count": 0, "title_full": "Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results", "spam_score": 0.0, "site_type": "news", "published": "2015-10-19T13:23:00.000+03:00", "replies_count": 0, "uuid": "61192a45c278252fee1c621214c817b64007a7d7"}, "author": "", "url": "http://www.bio-medicine.org/medicine-technology-1/Valeant-Pharmaceuticals-Reports-Third-Quarter-2015-Financial-Results-49035-1/", "ord_in_thread": 0, "title": "Valeant Pharmaceuticals Reports Third Quarter 2015 Financial Results", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "LAVAL, Quebec, Oct. 19, 2015 /PRNewswire/ -- \n2015 Third Quarter Results Total Revenues of $2.8 billion; an increase of 36% over the prior year despite negative foreign exchange impact of $172 million Same store sales organic growth of 13%; 5 th consecutive quarter of > 10% organic growth, driven by: Continued outperformance of U.S. businesses, particularly dermatology and contact lens Strong results in China (23%), South Korea (15%) and Mexico (10%) Total company growth was 8.2% volume and 4.4% price U.S. branded pharmaceuticals growth was 18.8% volume and 15.2% price Excluding the impact from genericization of Targretin Capsules during the quarter, same store sales organic growth would have been 14% Impact from generic Xenazine expected fully in fourth quarter Salix revenue was $461 million Strong Xifaxan script uptake following IBS-D approval Salix wholesaler inventory levels reduced from 3-3.5 months to 2-2.5 months GAAP EPS $0.14; Cash EPS $2.74, an increase of 30% over prior year despite the negative foreign exchange impact of $0.13 versus the prior year GAAP Operating Cash Flow $737 million, an increase of 19% over prior year; excluding the impact of foreign exchange, the increase was 26% Adjusted Operating Cash Flow $865 million, an increase of 12% over prior year; excluding the impact of foreign exchange, the increase was 18% Deals recently closed include Sprout, brodalumab, Synergetics and Amoun, which is expected to close later today \nFourth Quarter 2015 Guidance Total Revenue increased to $3.25 - $3.45 billion from $3.2 - $3.4 billion Cash EPS increased to $4.00 - $4.20 from $3.98 - $4.18 \nFull Year 2015 Guidance Total Revenue increased to $11.0 - $11.2 billion from $10.7 - $11.1 billion, Salix revenue expected to be ~$1.35 billion Cash EPS increased to $11.67 - $11.87 from $11.50 - $11.80 Adjusted Cash Flow from Operations of greater than $3.35 billion Same Store Sales Organic Growth of >10% for Q4 and FY 2015 \nValeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) today announced third quarter financial results for 2015. \n\"Today, we reported yet another consecutive quarter of strong financial results that exceeded expectations,\" stated J. Michael Pearson, chairman and chief executive officer. \"I am incredibly proud of the hard work and effort put forth by Valeant's employees around the world. I would also like to thank all the doctors who prescribe our products and the patients who use them. We will be discussing our outperformance on our conference call later today, as well as addressing the most frequently asked questions we have been hearing from our shareholders. With our strong product portfolio and growth prospects, we feel very confident in our future outlook and we are reaffirming our $7.5 billion EBITDA floor for 2016.\" \nConference Call and Webcast Information \nValeant will host a conference call and a live webcast along with a slide presentation today at 8:00 a.m. ET (5:00 a.m. PT) to discuss results for the 2015 third quarter. The dial-in number to participate on this call is (877) 876-8393, confirmation code 49576177. International callers should dial (973) 200-3961, confirmation code 49576177. A replay will be available approximately two hours following the conclusion of the conference call to October 26, 2015, and can be accessed by dialing (855) 859-2056 or (404) 537-3406, confirmation code 49576177. \nThe webcast and slide presentation will be hosted in the investor relations section of its corporate website at www.valeant.com . Participants should allow approximately five to ten minutes prior to the call's start time to visit the site and to download any streaming media software needed to listen to the webcast. An online archive of the webcast will be available following the end of the live call in the webcast archive portion of the investor relations section at www.valeant.com . \nAbout Valeant \nValeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorder, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com . \nForward-looking Statements \nThis press release may contain forward-looking statements, including, but not limited to, statements regarding our expected future performance, including guidance with respect to revenue, Cash EPS, adjusted cash flow from operations, and organic growth, and assumptions related to the impact of future generic competition. Forward-looking statements may generally be identified by the use of the words \"anticipates,\" \"expects,\" \"intends,\" \"plans,\" \"should,\" \"could,\" \"would,\" \"may,\" \"will,\" \"believes,\" \"estimates,\" \"potential,\" \"target,\" or \"continue\" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes. \nNon-GAAP Information \nTo supplement the financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the company uses non-GAAP financial measures that exclude certain items, such as amortization of inventory step-up, amortization of alliance product assets & property, plant and equipment step up, stock-based compensation step-up, contingent consideration fair value adjustments, restructuring, integration, acquisition-related and other costs, In-process research and development, impairments and other charges, (\"IPR&D\"), legal settlements outside the ordinary course of business, the impact of currency fluctuations, amortization including intangible asset impairments and other non-cash charges, amortization and write-down of deferred financing costs, debt discounts and ASC 470-20 (FSP APB 14-1) interest, loss on extinguishment of debt, (gain) loss on assets sold/held for sale/impairment, net, (gain) loss on investments, net, and adjusts tax expense to cash taxes. Management uses non-GAAP financial measures internally for strategic decision making, forecasting future results and evaluating current performance. By disclosing non-GAAP financial measures, management intends to provide investors with a meaningful, consistent comparison of the company's core operating results and trends for the periods presented. Non-GAAP financial measures are not prepared in accordance with GAAP. Therefore, the information is not necessarily comparable to other companies and should be considered as a supplement to, not a substitute for, or superior to, the corresponding measures calculated in accordance with GAAP. \nFinancial Tables follow.Valeant Pharmaceuticals International, Inc. Table 1 Condensed Consolidated Statements of Income (Loss)For the Three and Nine Months Ended September 30, 2015 and 2014Three Months EndedNine Months EndedSeptember 30,September 30,(In millions) 2015 2014 2015 2014 Product sales $2,748.2 $ 7,590.1 $5,868.1 Other revenues 38.6 33.3 120.0 115.4 Total revenues 2,786.8 2,056.2 7,710.1 5,983.5 Cost of goods sold (exclusive of amortization and impairments of finite-lived intangible assets shown separately below) 634.6 545.8 1,864.9 1,619.5 Cost of other revenues 13.6 15.0 43.1 45.3 Selling, general and administrative (\"SG&A\") 697.6 504.1 1,956.9 1,501.8 Research and development 101.6 59.1 238.5 186.9 Acquisition-related contingent consideration 3.8 4.0 22.6 14.8 In-process research and development impairments and other charges 95.8 19.9 108.1 40.3 Other (income)/expense 30.2 (232.0) 213.2 (275.7) Restructuring, integration, acquisition-related and other costs 82.6 63.3 300.3 341.1 Amortization and impairments of finite-lived intangible assets 679.2 393.1 1,629.8 1,113.9 2,339.0 1,372.3 6,377.4 4,587.9 Operating income (loss) 447.8 683.9 1,332.7 1,395.6 Interest expense, net (419.5) (257.6) (1,128.2) (742.3) Loss on extinguishment of debt - - (20.0) (93.7) Gain (loss) on investments, net - 3.4 - 5.9 Foreign exchange and other (34.0) (53.0) (99.5) (63.0) Income (loss) before (recovery of) provision for income taxes (5.7) 376.7 85.0 502.5 (Recovery of) provision for income taxes (57.4) 100.3 10.4 124.4 Net income (loss) 51.7 276.4 74.6 378.1 Less: Net income (loss) attributable to noncontrolling interest 2.2 1.0 4.4 (0.5) Net income (loss) attributable to Valeant Pharmaceuticals International, Inc. $49.5 $", "external_links": [], "published": "2015-10-19T13:23:00.000+03:00", "crawled": "2015-10-19T14:14:46.781+03:00", "highlightTitle": ""}